The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin ...

The rapid-acting insulin aspart biosimilar joins two prior long-acting insulin biosimilar products approved in 2021. Biosimilars are highly similar to already approved products and have no ...

Sliding scale insulin therapy involves following a chart of insulin dosages. A doctor will help a person with diabetes create this chart based on factors like how their body responds to insulin ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

Trials including commercially available formulations of insulin detemir or insulin glargine were compared with NPH. Pertinent English-language clinical trials published between 2000 and 2006 were ...

Crucially, the long-acting insulin was no worse than Tresiba when it came to rates of hypoglycaemia, when blood glucose levels dip too low, according to statistical comparisons between the drugs.

Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by the FDA. Approval of biosimilar products can ...

SILVER SPRING, Md., Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement ...